The REMEDY center will ensure research that improves patient care in the field of rheumatology and musculoskeletal diseases, with a major impact on individuals and society. The purpose of REMEDY is to develop excellent treatments and treatment strategies in rheumatology and musculoskeletal diseases through a broad approach to the research field. Our ambition is to conduct clinical studies with the potential to change clinical practice.
The center is established with Diakonhjemmet Hospital as host institution together with Oslo University Hospital, the University of Oslo, the Norwegian Rheumatism Association and MAGIC as affiliated partners.
Conduct high quality clinical trials to investigate the efficacy of drugs, surgical procedures, injections and non-pharmacological interventions, as well as personalised treatment strategies
Identify biomarkers and genetic/epigenetic markers of treatment efficacy and disease severity, and characterise and stratify early disease
Better understand underlying pain mechanisms to optimise treatment
Develop and evaluate strategies to detect, treat and prevent comorbidities
Develop and investigate the usability, efficacy and cost-effectiveness of personalised remote care
Investigate long-term effects, work participation and health economic consequences of different treatment strategies through linkage to national registries
Investigate health literacy, adherence to treatment and eHealth strategies to empower patients to manage their disease
In REMEDY there is also a national clinical consortium consisting of rheumatology departments and rehabilitation institutions from all over Norway. The purpose of the consortium is to enable patients from all over Norway to participate in multicenter studies that originate from REMEDY and to support participants in the consortium to initiate their own studies.
User participation in research will be central to all work packages. REMEDY has its own patient council and user representatives from this patient council will be part of the project group in the various projects. In addition, we will work closely with the Norwegian Rheumatism Association, which is also a partner in the center.
The Nor-vaC study is one of the projects featured in the National Report from the Specialist Health Service 2022 - Research and innovation for the benefit of patients.